These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 15639107

  • 1. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use.
    Bick RL, Frenkel EP, Walenga J, Fareed J, Hoppensteadt DA.
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):1-51, v. PubMed ID: 15639107
    [Abstract] [Full Text] [Related]

  • 2. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J, Iqbal O, Cunanan J, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA.
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Low- and ultra-low-molecular-weight heparins.
    Kakkar AK.
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):77-87. PubMed ID: 15171959
    [Abstract] [Full Text] [Related]

  • 8. Current trends in antithrombotic drug and device development.
    Fareed J.
    Semin Thromb Hemost; 1996 Mar; 22 Suppl 1():3-8. PubMed ID: 8807721
    [Abstract] [Full Text] [Related]

  • 9. Heparin and low-molecular-weight heparin.
    Gray E, Mulloy B, Barrowcliffe TW.
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [Abstract] [Full Text] [Related]

  • 10. An update on heparins at the beginning of the new millennium.
    Fareed J, Hoppensteadt DA, Bick RL.
    Semin Thromb Hemost; 2000 May; 26 Suppl 1():5-21. PubMed ID: 11011802
    [Abstract] [Full Text] [Related]

  • 11. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
    Ludwig RJ, Schindewolf M, Alban S, Kaufmann R, Lindhoff-Last E, Boehncke WH.
    Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
    [Abstract] [Full Text] [Related]

  • 12. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J, Leong WL, Hoppensteadt DA, Jeske WP, Walenga J, Wahi R, Bick RL.
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [Abstract] [Full Text] [Related]

  • 13. Pharmacology of the low-molecular-weight heparins.
    Fareed J, Hoppensteadt DA.
    Semin Thromb Hemost; 1996 Dec; 22 Suppl 2():13-8. PubMed ID: 8946614
    [No Abstract] [Full Text] [Related]

  • 14. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
    Fareed J, Ma Q, Florian M, Maddineni J, Iqbal O, Hoppensteadt DA, Bick RL.
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():89-104. PubMed ID: 15085470
    [Abstract] [Full Text] [Related]

  • 15. [Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles].
    Alban S.
    Hamostaseologie; 2008 Feb; 28(1-2):51-61. PubMed ID: 18278163
    [Abstract] [Full Text] [Related]

  • 16. [Low-molecular heparins: their mechanism of action, pharmacology and clinical use].
    Bashkov GV, Kalishevskaia TM, Golubeva MG, Solov'eva ME.
    Eksp Klin Farmakol; 1993 Feb; 56(4):66-76. PubMed ID: 8220023
    [No Abstract] [Full Text] [Related]

  • 17. New antithrombin-based anticoagulants.
    Desai UR.
    Med Res Rev; 2004 Mar; 24(2):151-81. PubMed ID: 14705167
    [Abstract] [Full Text] [Related]

  • 18. Role of heparin and low-molecular-weight heparins in the management of acute ischemic stroke.
    Padma V, Fisher M, Moonis M.
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):405-15. PubMed ID: 16716101
    [Abstract] [Full Text] [Related]

  • 19. [Anticoagulant and antithrombotic effects of low molecular weight heparin].
    Bashkov GV, Kalishevskaia TM, Bako N.
    Biull Eksp Biol Med; 1988 Oct; 106(10):399-402. PubMed ID: 2847825
    [Abstract] [Full Text] [Related]

  • 20. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins.
    Parody R, Oliver A, Souto JC, Fontcuberta J.
    Haematologica; 2003 Nov; 88(11):ECR32. PubMed ID: 14607764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.